PremiumThe FlyAptevo Therapeutics announces 1-for-20 reverse stock split Aptevo Therapeutics reports Q1 EPS ($4.39) vs. ($368.21) last year Aptevo Therapeutics provides program update for APVO711 PremiumThe FlyAptevo Therapeutics prices 1.76M shares at $1.19 in registered direct offering Aptevo Therapeutics Achieves Remission Success in AML Trial Aptevo reports two additional AML patients achieve remission in RAINIER trial PremiumThe FlyAptevo Therapeutics trading resumes Aptevo Therapeutics trading halted, volatility trading pause Aptevo Therapeutics announces results from cohort 1 in frontline AML trial 
